Compare Elder Pharma with Biocon Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs BIOCON - Comparison Results

BIOCON  
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA BIOCON ELDER PHARMA/
BIOCON
 
P/E (TTM) x -0.2 17.1 - View Chart
P/BV x 0.1 2.6 3.8% View Chart
Dividend Yield % 0.0 0.4 -  

Financials

 ELDER PHARMA   BIOCON
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
BIOCON
Mar-18
ELDER PHARMA/
BIOCON
5-Yr Chart
Click to enlarge
High Rs3801,188 32.0%   
Low Rs188305 61.6%   
Sales per share (Unadj.) Rs491.268.7 714.7%  
Earnings per share (Unadj.) Rs-3.27.6 -42.1%  
Cash flow per share (Unadj.) Rs14.414.0 103.1%  
Dividends per share (Unadj.) Rs01.00 0.0%  
Dividend yield (eoy) %00.1 0.0%  
Book value per share (Unadj.) Rs376.586.3 436.0%  
Shares outstanding (eoy) m20.54600.00 3.4%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x0.610.9 5.3%   
Avg P/E ratio x-89.398.9 -90.3%  
P/CF ratio (eoy) x19.753.4 36.9%  
Price / Book Value ratio x0.88.6 8.7%  
Dividend payout %013.2 0.0%   
Avg Mkt Cap Rs m5,833447,900 1.3%   
No. of employees `000NA6.1 0.0%   
Total wages/salary Rs m2,1799,311 23.4%   
Avg. sales/employee Rs ThNM6,705.8-  
Avg. wages/employee Rs ThNM1,514.2-  
Avg. net profit/employee Rs ThNM736.9-  
INCOME DATA
Net Sales Rs m10,08941,234 24.5%  
Other income Rs m2572,062 12.4%   
Total revenues Rs m10,34643,296 23.9%   
Gross profit Rs m-7928,291 -9.6%  
Depreciation Rs m3613,851 9.4%   
Interest Rs m2,756615 448.2%   
Profit before tax Rs m-3,6535,887 -62.1%   
Minority Interest Rs m0213 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m3,7130-   
Tax Rs m1251,569 8.0%   
Profit after tax Rs m-654,531 -1.4%  
Gross profit margin %-7.820.1 -39.0%  
Effective tax rate %-3.426.7 -12.9%   
Net profit margin %-0.611.0 -5.9%  
BALANCE SHEET DATA
Current assets Rs m9,24041,486 22.3%   
Current liabilities Rs m9,99821,413 46.7%   
Net working cap to sales %-7.548.7 -15.4%  
Current ratio x0.91.9 47.7%  
Inventory Days Days4664 72.4%  
Debtors Days Days6094 63.6%  
Net fixed assets Rs m10,12450,661 20.0%   
Share capital Rs m2063,000 6.9%   
"Free" reserves Rs m5,58248,808 11.4%   
Net worth Rs m7,73451,808 14.9%   
Long term debt Rs m4,88917,898 27.3%   
Total assets Rs m22,88299,897 22.9%  
Interest coverage x-0.310.6 -3.1%   
Debt to equity ratio x0.60.3 183.0%  
Sales to assets ratio x0.40.4 106.8%   
Return on assets %11.85.2 228.3%  
Return on equity %-0.88.7 -9.7%  
Return on capital %22.39.6 231.6%  
Exports to sales %3.00-   
Imports to sales %0.40-   
Exports (fob) Rs m307NA-   
Imports (cif) Rs m43NA-   
Fx inflow Rs m30712,058 2.5%   
Fx outflow Rs m1257,348 1.7%   
Net fx Rs m1814,710 3.8%   
CASH FLOW
From Operations Rs m11,7546,621 177.5%  
From Investments Rs m-561-6,840 8.2%  
From Financial Activity Rs m-6,762-2,397 282.1%  
Net Cashflow Rs m4,432-2,612 -169.7%  

Share Holding

Indian Promoters % 39.6 40.4 98.0%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 7.5 8.4 89.3%  
FIIs % 16.8 10.7 157.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 19.9 181.4%  
Shareholders   16,479 109,995 15.0%  
Pledged promoter(s) holding % 77.6 0.0 193,900.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   FULFORD INDIA  VENUS REMEDIES  STERLING BIOTECH  WOCKHARDT  SUVEN LIFESCIENCES  

Compare ELDER PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

BIOCON Announces Quarterly Results (1QFY20); Net Profit Down 11.5% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (4QFY19); Net Profit Down 53.8% (Quarterly Result Update)

Apr 26, 2019 | Updated on Apr 26, 2019

For the quarter ended March 2019, BIOCON has posted a net profit of Rs 705 m (down 53.8% YoY). Sales on the other hand came in at Rs 8 bn (down 34.7% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON LTD Announces Quarterly Results (3QFY19); Net Profit Up 169.2% (Quarterly Result Update)

Jan 28, 2019 | Updated on Jan 28, 2019

For the quarter ended December 2018, BIOCON LTD has posted a net profit of Rs 2 bn (up 169.2% YoY). Sales on the other hand came in at Rs 15 bn (up 45.6% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

BIOCON LTD Announces Quarterly Results (2QFY19); Net Profit Up 501.9% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, BIOCON LTD has posted a net profit of Rs 4 bn (up 501.9% YoY). Sales on the other hand came in at Rs 13 bn (up 36.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

BIOCON LTD Announces Quarterly Results (1QFY19); Net Profit Up 47.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, BIOCON LTD has posted a net profit of Rs 1 bn (up 47.2% YoY). Sales on the other hand came in at Rs 11 bn (up 20.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

My 7 Stocks to Buy Are Companies Which Will Be a Big Part of New India(The 5 Minute Wrapup)

Sep 19, 2019

The India we knew is changing. Here's how you can benefit from this change.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA 8-QTR ANALYSIS

COMPARE ELDER PHARMA WITH

MARKET STATS